Immunovant Inc. (IMVT), which reported positive results from its myasthenia gravis and chronic inflammatory demyelinating polyneuropathy studies of Batoclimab in March of this year, has two more key clinical readouts on the horizon.
Batoclimab works by targeting a specific protein in the body called the neonatal fragment crystallizable receptor (FcRn), which helps regulate the levels of immunoglobulin G (IgG) antibodies in the blood by preventing IgG degradation. In healthy people, IgG antibodies recognize and bind to foreign substances, marking them for destruction. In many autoimmune diseases, however, harmful IgG autoantibodies develop, triggering a harmful immune response where they recognize and bind to normal healthy tissue. By blocking FcRn, Batoclimab can reduce the levels of harmful antibodies that cause autoimmune diseases.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.